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Alterations in the expression and activity of the centrosomal
kinase, Aurora-Aserinethreonine kinase 15 (STK15), affect
genomic stability, disrupt the fidelity of centrosome duplication,
and induce cellular transformation. Here, we provide evidence that
p160ROCK, a Rho-associate serinethreonine kinase, associates
with Aurora-A in a protein complex with other STK15-associated
factors. Suppression of Aurora-A by small interfering RNA in HeLa
cells blocks the ability of centrosomes to organize normal mitotic
spindles, induces G2M cell cycle arrest, and promotes accumula-
tion of tetraploid cells. In many cases, one outcome of such
abnormalities is apoptosis. Introduction of a second genetic lesion,
suppression of p160ROCK by RNA interference, can rescue abnor-
mal mitotic spindle formation, release the G2M cell cycle arrest,
and alleviate apoptosis, leading to a greater accumulation of
aneuploid cells. These results suggest that Aurora-A and p160ROCK
act in a common genetic pathway that promotes and monitors
progression through G2M.
The eukaryotic centrosome is the microtubule-organizingcenter and is composed of two perpendicularly positioned
centrioles and surrounding amorphous pericentriolar materials
(for reviews, see refs. 1–6). Four groups of protein kinases are
found to regulate the centrosome replication cycle: cyclin-
dependent kinases (7–9), Polo-like kinases (10), NIMA kinases
(11), and Aurora kinases. In mammalian cells, the Aurora kinase
family has three members: Aurora-A, -B, and -C. Alterations in
the expression and activity of Aurora-Aserinethreonine ki-
nase 15 (STK15) affect genomic stability, disrupt the fidelity of
centrosome duplication, and induce cellular transformation (12–
15). Aurora-A is regulated by ubiquitin pathways and protein
phosphorylation (16–19). A kinesin-related protein (Eg5), cy-
toplasmic polyadenylation element-binding protein (CPEB), and
transforming acidic coiled-coil protein number 3 (TACC3) have
been found to be substrates of Aurora-A (20–23).
Recently, p160ROCK has been identified as a centrosome
component and functions in centrosome positioning and cen-
trosome-dependent exit from mitosis (24). p160ROCK is a
member of Rho-associated serine-threonine protein kinases.
p160ROCKRho-kinaseROK kinases are involved in various
cellular functions downstream of Rho, such as smooth muscle
contraction, stress fiber formation, and cytokinesis (25).
p160ROCK phosphorylates LIM kinase and mDia, which then
phosphorylates cofilin to regulate the Rho-induced reorganiza-
tion of cytoskeleton (26). p160ROCK has also been reported to
interact with CDC25A in transforming growth factor -induced
cell cycle arrest (27) and to be involved in tumorigenesis (28, 29),
and apoptosis (30). Here we provide biochemical and genetic
evidence that Aurora-A and p160ROCK associate physically and
functionally in a protein complex. These proteins interact ge-
netically, with suppression of p160ROCK alleviating the G2M
cell cycle arrest induced by inactivation of Aurora-A.
Materials and Methods
Cell Culture. Normal human foreskin fibroblast IMR90 cells were
immortalized by hTERT expression, and early passage HeLa
and LinXA (293Tt derivative as in ref. 31) were cultured as in ref.
32. To assess mitotic spindle reassembly capacity in vivo, micro-
tubules were disassembled with nocodazole and cold treatment
(32). The cells were incubated at 37°C for 10 min to promote
spindle reassembly. This process was monitored by anti--
tubulin indirect immunofluorescence. p160ROCK specific in-
hibitor Y27632 (Calbiochem) was used at 100 M in Fig. 2b.
Antibodies. Affinity-purified anti-Aurora-A, anti-GST-Aurora-A
sera (32), rabbit polyclonal anti--tubulin, mouse monoclonal
anti--tubulin, anti--tubulin (Sigma), rabbit anti-phospho-H3
(Ser-10, Upstate Biotechnology, Lake Placid, NY), mouse
monoclonal anti-BrdUrd (Amersham Pharmacia), rabbit poly-
clonal anti-MAD2 (Covance, Berkeley, CA), anti-p160ROCK
serum (a kind gift from Shuh Narumiya, Kyoto University,
Kyoto), anti-BubR1 and anti-Bub1 (kind gifts from S. Taylor,
Manchester, U.K.), anti-DDX3 and DDX6 (kind gifts from J.
Sommerville, University of St. Andrews, St. Andrews, Scotland
and A. H. Patel, Medical Research Council, Institute of Virol-
ogy, Glasgow, U.K.) were used. Another rabbit polyclonal
anti-p160ROCK antibody against the C-terminal 9 aa (VKNTS-
GKTS) of p160ROCK was affinity-purified as in ref. 32.
Immunoprecipitation, Immunofluorescence, Immunoblot, and Aurora-A
Depletion Assay. Immunoprecipitation, immunofluorescence, and
immunoblotting were as described in ref. 32. Denaturing immu-
noprecipitation was done as in ref. 33. To measure how much
p160ROCK associates with Aurora-A in vivo, we used increasing
amounts of anti-GST-Aurora-A serum, and found that Auro-
ra-A in 1  106 immortalized IMR90 cells can be 90% depleted
by using 50 l of anti-GST-Aurora-A serum. In Fig. 1c, the same
amount of anti-Aurora-A antibody was used and images on
immunoblot were captured with Alphaimager 2200 and quan-
tified by CHEMILMAGER V5.5 program (Alpha Innotech, San
Leandro, CA).
35S-Labeling of Cells. IMR90 or cancer cell lines (2  106 cells)
were labeled with 35S-translabeling mixtures (Easy tag express
[35S] protein-labeling mix, 1,175 Cimmol; NEN) for 4 h. The
cells were lysed, and immunoprecipitations were as in ref. 32.
Peptide Sequencing, MS Analysis, and Sequence Identification. Pre-
parative immunoprecipitates from 2.5  108 IMR90 cells by
using 1.5 mg of affinity-purified anti-Aurora-A antibody were
resolved in 10% or 12% SDS-polyacrylamide gel and stained by
Bio-Safe Coomassie G250 (Bio-Rad) or sequencing-grade Coo-
massie blue G250 (Sigma). Individual bands were excised and
digested with trypsin, and peptides were fractionated by RP-
HPLC. The MS sequencing was done in the Bio-medical Mass
Spectrometry Facility at Washington University, St. Louis, as in
ref. 34.
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RNA Interference (RNAi) in Transient Transfection. To design target-
specific small interfering RNA (siRNA) duplexes, AA(N19)dTdT
type sequences were selected from the ORFs of the p160ROCK
(AAGGTGATTGGTAGAGGTGCA), Aurora-A (AAGCA-
CAAAAGCTTGTCTCCA), and GFP (TCAGCGTGTCCGGC-
GAGGGCGA) (35). The selected sequences were submitted to
BLAST searches against the nonredundant protein database in
National Center for Biotechnology Information to make sure that
only the selected genes were targeted. The 21-nt RNAs purchased
form Dharmacon (Lafayette, CO). In brief, 100 nM siRNA was
used with transfection reagent Oligotransfectamine (Invitrogen) in
HeLa cell transfections as in ref. 35. The 24-, 48-, and 72-h time
points had one, two, and three rounds of transfections, respectively.
Cells were assayed 24 h after the last transfection.
Flow Cytometry. Transfected HeLa cells were trypsinized and
fixed for flow cytometry on Becton Dickinson FACSCalibur or
LSRII as in ref. 36. The data were processed for cell cycle
distribution by MODFIT V.2 (Macintosh) or V.3 (PC).
Apoptosis Assay. HeLa cells transfected in six-well cell-culture
plates were trypsinized. The cells together with the culture media
were spun down at 1,000 rpm in a tabletop centrifuge, and cells
were stained with Hoechst 33342 to visualize the nuclei DNA
morphology. Cells with intact uniform nuclei were counted as
live cells and cells with fragmented nuclei, a signature of
apoptosis cell, were counted as apoptotic cells (37). Annexin
V-FITC apoptosis detection kit II (BD Pharmingen) and ter-
minal deoxynucleotidyltransferase-mediated dUTP nick end-
labeling assay (In Situ cell death detection kit, Roche Applied
Science) were used according to the manufacturers’ instructions.
Results and Discussions
To identify regulators and substrates of Aurora-A kinase, im-
mortalized human IMR90 fibroblast cells were labeled with 35S
and Aurora-A was immunoprecipitated from cell lysates with
affinity purified polyclonal anti-Aurora-A antibodies. Nine pro-
tein bands associated specifically with the antibody (Fig. 1a). We
named the immunoprecipitated Aurora-A-bound protein
STK15-associate factors (SAFs; see below).
The integrity of STK15 complexes is compromised in various
breast and prostate cancer cell lines tested. However, SAF160
appears in every cell line examined, pointing to the potential
importance of its association with Aurora-A (Fig. 1a). To
identify components of the Aurora-A complex, Aurora-A-
associated protein bands were excised and analyzed by matrix-
assisted laser desorption ionization–time-of-f light MS and elec-
trospray ionization MSMS. Mass fingerprinting indicated that
the 46-kDa protein was Aurora-A and that SAF160 was
p160ROCK. Immunoblotting Aurora-A immunoprecipitates
showed that anti-Aurora-A specifically immunoprecipitated Au-
rora-A, and p160ROCK, SAF68, and SAF55 (also identified as
DDX3 and DDX6 by matrix-assisted laser desorption ioniza-
tion–time-of-f light) (Fig. 1b). Immunoblot analysis demon-
strated that -tubulin is not present at detectable levels in the
SAF immunocomplex (data not shown). Therefore, it is unlikely
that the purified SAF complex represents part of the centrosome
that is indirectly associated with Aurora-A through -tubulin.
TPX2 has been found to interact with Aurora-A by immuno-
precipitation (38). However, we did not see a band of 100 kDa
corresponding to TPX2 (Fig. 1a). Use of different anti-Aurora-A
antibodies, cell lines, and labeling methods may account for this
discrepancy in the immunoprecipitation results.
To examine whether SAFs coexist with Aurora-A in a large
multiprotein complex, IMR90 lysates were fractionated by
FPLC. All the identified proteins cofractionated with Aurora-A
on Mono S and Mono Q ion-exchange columns and on a third
Superose 6 gel filtration column (Fig. 5a, which is supporting
information on the PNAS web site). On Superose 6, Aurora-A
split into two distinct peaks, indicating that Aurora-A exists in
multiple protein complexes (Fig. 5b and ref. 32). Immunodeple-
tion with anti-GST-Aurora-A antibody in IMR90 cell lysates
suggested that roughly half of endogenous p160ROCK associ-
ates with Aurora-A (Fig. 1c), either at the centrosome or in the
cytoplasm (24).
We used RNAi to investigate consequences of suppressing
Aurora-A or p160ROCK in HeLa cells. siRNAs dramatically
reduced the expression of targeted proteins (Fig. 2a). Immuno-
fluorescence stains with anti-Aurora-A and -p160ROCK also
confirmed the depletions. The depletion of Aurora-A also
Fig. 1. Aurora-A and p160ROCK associate in a protein complex. (a) IMR90 cells, several prostate (LNCaP-FGC, PC-3, DU145, and NCI-H660), and breast (T-47D,
BT549, MCF-7, and MDA-MB-468) cancer cell lines were labeled with [35S]methionine. Cell lysates were immunoprecipitated with affinity-purified anti-Aurora-A
antibody (Aurora-A lanes) or anti-Aurora-A plus cognate antigen polypeptide (Aurora-Acognate polypeptide lanes) and were resolved on SDS-10%
polyacrylamide gel and subjected to autoradiography. SAFs with numbers indicate the apparent molecular mass on the gel, starting from the largest component
(160 kDa). Molecular mass markers are indicated on the left. (b) Anti-p160ROCK, -SAF68, -SAF55, and -Aurora-A immunoblotting on anti-Aurora-A immuno-
precipitates from IMR90 cells. (c) IMR90 cell lysates that were either titrated with anti-GST-Aurora-A to remove Aurora-A protein, or with same amount of
preimmune sera as a control were subjected to immunoblotting with anti-p160ROCK and Aurora-A. Tubulin was used as a loading control.
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significantly reduced the p160ROCK protein level (Fig. 2a),
consistent with the notion that two proteins interact in a complex
in vivo (39).
Twenty-four hours after transfection of siAurora-A, cells
became rounder and grew more slowly than the control siGFP-
transfected cells. Flow cytometry showed a significant increase
in G2M phase cells in comparison with that observed in the
control siGFP- or siROCK-treated cells (Fig. 2b Right). Notably,
this cell cycle phenotype could be alleviated by simultaneous
cotransfection of siRNAs directed against Aurora-A and
p160ROCK (Fig. 2b Right, siAurora-AsiROCK). Correspond-
ingly, a ROCK kinase specific inhibitor, Y27632, also showed a
dosage-dependent suppression of the G2M arrest phenotype in
siAurora-A-transfected cells (Fig. 2b Right, siAurora-
AY27632). These results demonstrate an epistatic relationship
between Aurora-A and p160ROCK and indicate that they
function in the same genetic pathway.
The observed phenotypes were also confirmed by immuno-
fluorescence staining of cells with anti-phospho-H3 antibody, a
mitotic marker that specifically labels cells from the beginning of
prophase to the end of anaphase (Fig. 2c). Quantitation of
anti-phospho-H3 staining by flow cytometry supported inter-
pretations from the immunofluorescence studies (data not
Fig. 3. Depletion of Aurora-A in HeLa cells causes abnormal mitotic spindles
and split centrosomes in mitotic arrested cells, but further deletion of
p160ROCK alleviates the phenotype. HeLa cells transfected with siGFP (a),
siAurora-A (b), siROCK (c), or both (d) were subjected to immunofluorescence
analysis with anti--tubulin to visualize mitotic spindles, anti--tubulin to
visualize centrosomes, and Hoechst 33342 to visualize nuclei DNA morphol-
ogies. The merge lane combines the anti-- or anti--tubulin images together
for colocalization. In c cells were treated with nocodazole and cold to dissipate
the microtubule networks. The mitotic spindles were allowed to reassemble
for 10 min in 37°C.
Fig. 2. Depletion of Aurora-A in HeLa cells induces G2M cell cycle arrest and
apoptosis, but further deletion of p160ROCK alleviates this phenotype. HeLa
cells with siGFP, siAurora-A, siROCK, or both, were used at 48 h after trans-
fection. (a) Cell lysates (25 g) were subjected to immunoblot assay by anti-
Aurora-A, -p160ROCK, and -tubulin. The proteins are indicated on the left. (b)
Cells treated with various siRNAs andor Y-27632 were collected, fixed, and
analyzed by flow cytometry. The blue portion indicates the diploid cells. The
red portion indicates apoptotic cells, and the green portion indicates tet-
raploidaneuploid cells. 1C, 2C, and 4C DNA contents are also indicated by
arrows. (c, complete haploid DNA content). (c) Cells were stained for mitotic
marker by using anti-phospho-H3 antibody, counterstained by Hoechst 33342
to visualize nuclei, and subjected to immunofluorescence microscopy. (d) Cells
were collected including the floating cells in the media. Precipitated cells were
resuspended in mounting media supplemented with Hoechst 33342 to stain
DNA in the nuclei, and checked under a microscope for apoptotic cells. (e)
HeLa cells were plated in six-well plates and transfected with siRNAs. At the
indicated time, cells were collected and counted. Purple line, siGFP; yellow
line, siROCK; green line, siAurora-A; blue line, siAurora-AsiROCK. In c–e,
three independent experiments were performed and in each experiment,
300 cells were counted. Error bars are labeled on the top.








shown). BrdUrd incorporation to assess the S-phase population
did not show a noticeable difference in the transfected cells at
any time point (data not shown). The significantly prolonged
mitotic phase correlated with an increased frequency of apo-
ptosis (Fig. 2d), which was also confirmed by annexin V staining
and terminal deoxynucleotidyltransferase-mediated dUTP nick
end-labeling assays (data not shown) and a decrease in surviving
cell numbers as measured by plotting growth curves (Fig. 2e).
Again, cotransfection of siROCK together with siAurora-A
partially rescued the apoptotic phenotype (Fig. 2 d and e).
Because Aurora-A is a centrosomal kinase, we next assessed
the integrity of mitotic spindles and examined centrosome and
nuclear morphologies in siAurora-A-transfected cells (Fig. 3).
Most mitotic cells contained abnormal spindles with disorga-
nized arrays of microtubules and fewer and shorter spindles than
in normal control cells (Fig. 3b, anti--tubulin columns in
siAurora-A images). In addition, comparison of the spindle
lengths, intensities, and levels of the anti--tubulin stains in
siAurora-A-treated cells with those of siGFP control cells
showed that the spindle microtubule networks in Aurora-A-
depleted cells did not extend to the condensed prometaphase
chromosomes (Fig. 3 a and b, anti--tubulin columns). Some of
the abnormal spindles still apparently radiated from centro-
somes (Fig. 3b). Others had multiple origins that did not always
colocalize with centrosomes or concentrations of -tubulin (Fig.
3b, anti--tubulin stains indicated by triangles). The portion of
cells with abnormal spindles increased dramatically over the time
course of the experiment (Fig. 4a). This outcome is the most
prominent defect in the siAurora-A-transfected cells. Anti--
tubulin staining showed that with abnormal mitotic spindles,
multiple concentrated spots of -tubulin occurred in the cyto-
plasm (Fig. 3b, anti--tubulin spots indicated with arrows).
Suppression of Aurora-A also induced centrosome amplification
in interphase cells (Fig. 4b). Although chromosomes condensed
at prometaphase in arrested mitotic cells, virtually no normal
metaphase and anaphase mitotic figures were found in these
transfected cells, suggesting cells arrested at prometaphase (Fig.
3b). Live cell imaging over a 4-h time course showed no
progression of the arrested cells to metaphase, whereas control
cells progressed from prometaphase through anaphase in 50
min (data not shown). siRNAs to Aurora-A also resulted in a
significant accumulation of binucleated cells (Fig. 4c). Many
nuclei had satellite micronuclei around the major interphase
nucleus. In addition, many nuclei showed irregular undefined
edges and shapes, a phenotype that often accompanies genomic
instability and aneuploidy. The cell population with these un-
usual nuclear morphologies increased dramatically over the time
course of the experiment (Figs. siAurora-A, 4C portion 2b Left,
and 4c), indicating an increase in genomic instability of the cells.
The mitotic spindle defects we observed here are closely resem-
ble to those recently observed in Aurora-A-depleted HeLa cells
(38, 40).
In siROCK-transfected cells, the number of cells with multiple
mitotic spindles and the number of cells with apparent centro-
some amplification in interphase cells increased significantly in
comparison with siGFP control cells (Fig. 4 a and b). A dramatic
Fig. 4. Depletion of Aurora-A, p160ROCK, or both induces genomic instability. HeLa cells were analyzed 24, 48, and 72 h after transfection with siRNAs for
mitotic spindle (a), centrosome (b), and nuclear (c) morphologies. (a) Spindles that can organize arrays of extended microtubules were counted as normal, either
with one or two spindles, or with multiple (2) spindles. Disorganized, distinctively fewer, and shorter spindles were counted as weak spindles (either one or
two, or multiple). (b) Centrosomes were grouped according to their numbers in either single or multiply (2) nucleated cells. (c) Nuclei with free chromosome(s)
(satellite nuclei), lagging chromosomes between two cells, string-like (abnormal chromosomes that were fragmented or unraveled), misplaced (positions in the
cells dramatically deviated form wild-type controls), were counted as fragmented nuclei. The nuclei with perfectly round, smooth edges were counted as uniform
nuclei. Cells with more than two nuclei were counted as cells with multiple nuclei. Three independent experiments were conducted and in each experiment, at
least 100 mitotic (a) or 200 (b and c) cells were examined.
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increase in mitotic spindle reassembly capacity was also observed
in siROCK-transfected cells (see Materials and Methods). Eighty
percent of mitotic cells showed multiple, reassembled mitotic
spindle networks after transient treatment with nocodazole (Fig.
3c, anti--tubulin columns in siROCK images), in comparison
with 20% of control cells. The result showed the siROCK-
transfected cells are highly prone to reassembling inappropriate
mitotic spindles using nascent -tubulin spots. In accordance
with this result, we observed an increase in aneuploid cells (Figs.
siROCK, 4C portion 2b Left, and 4c). Also, siROCK transfection
caused nuclear fragmentation (Fig. 4c). However, a dramatic
increase did not occur in multinucleated cell populations (Fig.
4c). This result suggests that depletion of p160ROCK alone can
give rise to aneuploid cells, although to a lesser degree than does
loss of Aurora-A.
Again, we found the mitotic arrest caused by suppression of
Aurora-A was alleviated by coincident depletion of p160ROCK
(Fig. 2 b Right, siAurora-AsiROCK, and c). Cotransfection of
both siAurora-A and siROCK led to assemble of functional
mitotic spindles (Fig. 3d, anti--tubulin columns in siAurora-
AsiROCK images), completion of mitosis, regrouping of split
centrosomes into two functional groups for organizing bipolar
spindles (Fig. 3d, anti--tubulin columns in siAurora-
AsiROCK images), and greater accumulation of aneuploid
cells (Figs. siAurora-AsiROCK, 4C portion 2b Left, and 4c).
The immunoprecipitated Aurora-A not only phosphorylated
an artificial substrate, myelin basic protein, but also phosphor-
ylated a p160 in the SAF complex (Fig. 6 a and b, which is
published as supporting information on the PNAS web site). This
finding was confirmed by denaturing IP to be p160ROCK (Fig.
6c). Aurora-A also phosphorylated another protein, p82, in
purified centrosomes (Fig. 6 a and b). Phosphorylation of
p160ROCK in the immunoprecipitated Aurora-A complex can
be specifically increased in cells transfected with constructs
encoding Aurora-A, but not a mutant Aurora-A K162M, which
lacks kinase activity (41) (Fig. 6d). In fact, [32P]orthophosphate
labeling indicated that phosphorylation of p160ROCK in the
cells expressing a kinase dead Aurora-A K162M mutant appre-
ciably decreased, suggesting that Aurora-A is responsible, at
least in part, for p160ROCK phosphorylation in vivo (Fig. 6e,
comparing P-p160ROCK band intensity in K162M lane with
those in other control lanes). Phosphoamino acid analysis of
excised 32P-labeled p160ROCK band showed that only serine
residue(s) are phosphorylated (Fig. 7a, which is published as
supporting information on the PNAS web site). In vitro kinase
assays with various GST-p160ROCK fusion proteins as sub-
strates for Aurora-A (Fig. 7b, all fusion proteins started from N
terminus of p160ROCK and ended at the indicated amino acids)
showed GST-p160ROCK1034 was significantly labeled, but not
GST-p160ROCK726 or other fusion proteins (Fig. 7c), suggest-
ing the phosphorylated serine residues are located between 726
and 1,034 aa of p160ROCK.
A G2M delay phenotype had been reported after overex-
pression of Aurora-A in HeLa cells (42). A similar mitotic defect
is also observed on Aurora-A loss-of-function in Drosophila
melanogaster and in S2 cells (ref. 43 and data not shown) and
most recently in HeLa cells (40, 44). These results together with
our observation indicate that balance of Aurora-A protein in the
cell is critical and that either down- or up-regulation of its protein
level will compromise its function and lead to mitotic defects.
Suppression of aurora-A (aurora-1) in Caenorhabditis elegans by
RNAi does not affect centrosome separation, but mitotic spindle
formation (45), similar to what we observed here in HeLa cells.
However, in D. melanogaster syncytial embryos, aurora muta-
tions cause centrosome separation defects, which result in mo-
nopolar spindles and abnormal mitoses. The differences between
these observed phenotypes could be due to cell type-specific
functions of Aurora kinases. However, we favor the notion that
different genetic lesions (e.g., point mutation versus nearly, but
not complete suppression by RNAi versus null mutations) leads
to different phenotypic outcomes. Although a causal relation-
ship between phosphorylation of p160ROCK by Aurora-A and
suppression of mitotic arrest has not been firmly established
here, our results indicate that p160ROCK acts downstream of
Aurora-A in a common genetic pathway and phosphorylation of
p160ROCK by Aurora-A may mimic the depletion of
p160ROCK to bypass the mitosis arrest caused by Aurora-A
inactivation.
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